The effect of metformin on apoptosis in a breast cancer presurgical trial

M Cazzaniga*,1,7, A DeCensi2,7, G Pruneri3,4, M Puntoni5, L Bottiglieri3, C Varricchio1, A Guerrieri-Gonzaga1, O D Gentilini6, G Pagani6, P Dell’Orto3, M Lazzeroni1, D Serrano1, G Viale3,4 and B Bonanni1

1Division of Cancer Prevention and Genetics, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy; 2Division of Medical Oncology, E.O. Ospedali Galliera, Mura delle Cappuccine 14, 16128 Genoa, Italy; 3Department of Pathology and Laboratory Medicine, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy; 4University of Milan, School of Medicine, Milan, Italy; 5Clinical Trial Unit, Office of the Scientific Director, E.O. Ospedali Galliera, Mura delle Cappuccine 14, 16128 Genoa, Italy and 6Division of Breast Surgery, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy

Background: Metformin has been associated with antitumour activity in breast cancer (BC) but its mechanism remains unclear. We determined whether metformin induced a modulation of apoptosis by terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) overall and by insulin resistance status in a presurgical trial.

Methods: Apoptosis was analysed in core biopsies and in surgical samples from 100 non-diabetic BC patients participating in a randomised trial of metformin vs placebo given for 4 weeks before surgery.

Results: Eighty-seven subjects (45 on metformin and 42 on placebo) were assessable for TUNEL measurement at both time points. TUNEL levels at surgery were higher than that at baseline core biopsy (P<0.0001), although no difference between arms was noted (metformin arm: median difference surgery-biopsy levels +4%, interquartile range (IQR): 2–12; placebo arm: +2%, IQR: 0–8, P = 0.2). Ki67 labelling index and TUNEL levels were directly correlated both at baseline and surgery (Spearman’s r = 0.51, P < 0.0001). In the 59 women without insulin resistance (HOMA index <2.8), there was a higher level of TUNEL at surgery on metformin vs placebo (median difference on metformin +4%, IQR: 2–14 vs +2%, IQR: 0–7 on placebo), whereas an opposite trend was found in the 28 women with insulin resistance (median difference on metformin +2%, IQR: 0–6 vs +5%, IQR: 0–15 on placebo, P-interaction = 0.1).

Conclusion: Overall, we found no significant modulation of apoptosis by metformin, although there was a trend to a different effect according to insulin resistance status, with a pattern resembling Ki67 changes. Apoptosis was significantly higher in the surgical specimens compared with baseline biopsy and was directly correlated with Ki67. Our findings provide additional evidence for a dual effect of metformin on BC growth according to insulin resistance status.

Recent evidence indicates a strong relationship between the presence of hyperinsulinemia, insulin resistance and breast cancer (BC). This condition partly explains the relationship between obesity and BC risk in postmenopausal women (Renehan et al, 2008; Gunter et al, 2009; Decensi and Gennari, 2011). There is a great interest in exploring the possibility that antidiabetic therapies lowering insulin levels may decrease BC incidence and mortality.

Metformin, an oral biguanide, has been used worldwide to treat type 2 diabetes and pre-diabetic condition for more than 40 years because of its good tolerability profile and low cost (Drugs.com, 2011 http://www.drugs.com/pro/metformin-html). Recent epidemiological and observational studies have shown an association between metformin use and reduced cancer incidence and cancer-related mortality, compared with other antidiabetic treatments in
diabetic patients (Evans et al, 2005; Bowker et al, 2006; Decensi et al, 2010). However, the comparator groups are mostly formed by users of insulin and sulphonylureas, two drugs possibly associated with increased cancer risk (Johnson and Gale, 2010; Soranna, et al, 2012). Although the metformin mechanism of action is still under investigation, preclinical studies suggest a direct antineoplastic activity (Cazzaniga et al, 2009), entailing both insulin-dependent and -independent mechanisms (Zhou et al, 2001; Zakikhani et al, 2006; Mulligan et al, 2007; Goodwin et al, 2008, 2009; Gonzalez-Angulo and Meric-Bernstam, 2011). In humans, it is unclear whether these effects apply also to non-diabetic subjects or to subjects without insulin resistance. We have recently shown that a 4-week pre-surgical treatment with metformin in BC patients does not affect the proliferation antigen Ki67 labeling index (LI) overall, but does lower tumour proliferation in women with insulin resistance as measured by the homeostasis model assessment index (HOMAi, fasting blood glucose (mmol l\(^{-1}\)) \times \text{insulin (mU l}^{-1})/22.5 > 2.8) or with body mass index (BMI) > 27 kg m\(^{-2}\) (Bonanni et al, 2012). These effects were particularly evident in the luminal B molecular subtype, suggesting a potential therapeutic effect of metformin in this tumour type.

In a recently completed window of opportunity, single-arm trial, Niraula et al (2012) have shown, in comparison with baseline, an increase in apoptosis or programmed cell death, as measured by terminal deoxynucleotidyl transferase dUTP nick end labelling (TUNEL) and a decrease of Ki67 LI after a median of 3 weeks of metformin before surgery. The aim of the current analysis was to determine whether metformin can modulate apoptosis overall and by HOMAi in a large group of subjects participating in a randomised presurgical trial.

**PATIENTS AND METHODS**

At the European Institute of Oncology (IEO), Milan, Italy, we conducted a randomised, phase II, double blind, placebo-controlled trial on women with stage I–IIIa BC who were candidates for elective surgery. The study was conducted with the approval of the European IEO ethical committee. Having provided written informed consent (for participation in the trial and publication of the data when appropriate), the patients received either metformin or placebo for 4 weeks before surgery (trial number 5425/408, EudraCT 2008-004912-10). Baseline core biopsies of the tumour tissue and blood samples were obtained at study entry and before surgery to allow pre-/post-treatment comparisons. A detailed description of study design and primary end point Ki67 LI has recently been published (Bonanni et al, 2012). Briefly, 200 non-diabetic patients were randomly assigned to metformin, 850 mg tablets once daily for 3 days followed by 850 mg b.i.d. or placebo after dinner from day 4 to 28.

In the present analysis, we analysed the apoptotic cell nuclei by TUNEL from core biopsies and their paired surgical samples from the last 100 recruited subjects. On the basis of Niraula et al (2012), this number was sufficient to detect as significant with a power of at least 80% a 30% relative increase from baseline in TUNEL levels.

**Immunohistochemistry.** Ki67 LI, oestrogen and progesterone receptors and Her2/neu were assessed at the IEO Division of Pathology in all core biopsies and post-treatment surgical samples, as previously described (Bonanni et al, 2012).

**Assessment of the AI.** Apoptotic cell nuclei were identified by the TUNEL method, using an in situ apoptosis detection kit (TREVIGEN Inc, 8405 Helgerman Ct., Gaithersburg, MD, USA), according to the manufacturer’s instructions. Briefly, after rehydration in ethanol and fixation in 3.7%-buffered formaldehyde, sections were digested with protease solution (23 min at 37 °C), immersed in TdT labelling buffer, covered with the labelling reaction mix (37 min–1 h), immersed in streptavidin solution and dyed with DAB. The apoptotic index (AI) was assessed by counting any nuclear brown staining in the cells from invasive carcinoma in 10 microscopic fields at \(\times40\) magnification (HPF). Cases of invasive carcinoma with an extent smaller than that observed by summing the diameter of 10 HPF were deemed not to be assessable for AI.

**Circulating biomarkers.** Morning fasting blood samples were collected between 0800 and 1000 hours at baseline and at treatment completion. Serum aliquots for insulin were measured on frozen samples stored at \(-80\) °C until assayed, whereas glucose was measured on fresh samples. Insulin was measured with an electrochemiluminescence immunoassay by COBAS e411 (Roche Diagnostics, Mannheim, Germany). Serum concentrations of glucose was determined by COBAS INTEGRA 800 (Roche Diagnostics). A HOMAi greater than 2.8 was the cutoff of insulin resistance based on the population study conducted in Northern Italy (Bonora et al, 1998).

**Statistical analysis.** Sample size calculation and statistical methods of the current clinical trial have been previously detailed (Bonanni et al, 2012). In this analysis, because of the highly skewed distribution of TUNEL, results were mainly reported as median and interquartile ranges (IQR) in tables and graphically represented by boxplots. The Wilcoxon rank-sum (the Mann–Whitney) test was used to test the difference between arms, and the Wilcoxon-matched pair signed-rank test was employed for the differences between biopsy and surgery differences within arms. To adjust for age, BMI and Ki67 LI at baseline, linear modelling was also adopted with TUNEL values, using post-treatment TUNEL (square root transformed because of the highly skewed distribution rich of 0 and 1 values) as the response variable, and baseline TUNEL and treatment arm as explanatory variables. Treatment \(\times\) covariate interaction terms were tested for BMI and HOMAi index, and a \(P\)-value for interaction < 0.1 was considered as statistically significant in order to decrease the false-negative rate.

All analyses were performed using STATA software, version 11 (StataCorp., College Station, TX, USA). Two-tailed probabilities were reported at \(P<0.05\) significance level.

**RESULTS**

The main host and tumour characteristics of the 100 subjects included in this analysis are reported in Table 1. All variables were evenly distributed between arms and no significant difference with the original cohort was observed.

Analysis of the apoptotic cell nuclei by TUNEL was feasible in 87 core biopsies and their paired surgical samples (45 on metformin and 42 on placebo). The median TUNEL levels at surgery was 10%, IQR: 4–20, in the metformin arm and 8%, IQR: 3–15, in the placebo arm. These levels were significantly higher \((P<0.0001)\) when compared with baseline biopsy in both arms (median difference surgery-biopsy levels in metformin arm: \(+4\%\), IQR: 2–12; placebo arm: \(+2\%\), IQR: 0–8; Figure 1). The difference in TUNEL levels at surgery between arms was not significant \((P=0.2\) from a linear model adjusted for TUNEL at baseline, age, BMI and Ki67 LI at baseline).

When we considered the interaction between treatment and the HOMAi on TUNEL, we found a borderline significant trend to a different metformin effect according to the HOMAi \((P=0.1\), Figure 2). Specifically, median (IQR) TUNEL levels at surgery among the 59 women without insulin resistance (HOMAi<2.8) was 10% (6–22) on metformin compared with 6% (3–12) on placebo \((P=0.048)\), with a difference between surgery and biopsy equal to \(+4\%\), IQR: 2–14 in the metformin arm vs \(+2\%\), IQR:...
Our recent window of opportunity trial had shown that a 4-week pre-surgical treatment with metformin did not affect proliferative activity overall as measured by Ki67 LI. However, there was a differential effect on Ki67 LI according to insulin resistance status. In the subgroup of patients with insulin resistance or who were overweight (BMI > 27 kg m⁻²), metformin therapy decreased Ki67 LI levels, particularly in the luminal B molecular subtype, whereas an opposite trend was noted in women with HOMAi 2.8 or BMI > 27 kg m⁻².

In the present study based on the last 100 enrolled participants, we report the following three main findings: (1) apoptosis levels measured by TUNEL are higher in the surgical specimens compared with baseline core biopsy; (2) apoptosis is directly correlated with proliferation as measured by Ki67 LI, that is, TUNEL is high when Ki67 LI is high; and (3) the metformin effects on apoptosis mirrored those measured by Ki67 LI, that is, TUNEL is high when Ki67 LI is high.

DISCUSSION

There is evidence to suggest that insulin resistance, hyperinsulinaemia and the associated changes in IGFs, sex hormones, inflammatory and adipokine molecules levels are correlated with breast carcinogenesis (Calle and Kaaks, 2004; Pollak et al, 2004; Renehan et al, 2006; Yee, 2006). Abnormal tumour metabolism has therefore become a potentially new therapeutic target because several of these pathways are involved in carcinogenesis progression and potentially reversible by preventive and therapeutic interventions (Vander Heiden et al, 2009).

Antidiabetic therapies that lower or sensitize insulin effects may decrease BC incidence or its related mortality. Epidemiological (Decensi et al, 2010; Bosco et al, 2011, preclinical (Zakikhani et al, 2006; Sahra et al, 2008) and also clinical data by a recent retrospective analysis of patients receiving neoadjuvant chemotherapy and metformin (Jiralespong et al, 2009) suggest that this antidiabetic drug may exert antitumour activity through indirect (insulin mediated) and direct mechanisms of action, leading to a decreased proliferative activity of epithelial cells (Guppy et al, 2011).

The higher TUNEL levels in the surgical specimen compared with baseline biopsy may be explained by a sampling effect in the first place. Given the scarcity of apoptosis in BC, the small tissue availability in the biopsy specimen may underestimate real levels that become evident in the surgical specimen.

0–7 in the placebo arm. Conversely, among the 28 women with insulin resistance (HOMAi 2.8), median and IQR TUNEL levels was 6% (4–10) on metformin vs 9% (6–18) on placebo (P = 0.3), with a median difference pre-/post-treatment difference equal to +2%, IQR: 0–6 in the metformin arm vs +5%, IQR: 0–15 in the placebo arm. Interestingly, we found a highly significant positive correlation between Ki67 LI and TUNEL levels both at baseline (Figure 3) and surgery (Figure 4) (Spearman’s ρ = 0.5 and 0.6, respectively, P < 0.0001).

Table 1. Tumour characteristics by allocated arm

|                          | Metformin (n = 50) | Placebo (n = 50) | P* |
|--------------------------|-------------------|-----------------|----|
| Age (median, IQR)        | 50, 45–62         | 49, 45–57       | 0.5|
| Body mass index (median, IQR) | 24.2, 20.8–26.8 | 24.7, 21.4–28.3 | 0.6|
| HOMA index (median, IQR) | 2.18, 1.15–3.13   | 2.18, 1.72–3.15 | 0.4|
| Ki67 LI (median, IQR)    | 21, 12–38         | 20, 15–34       | 0.9|
| T stage (n, %)           |                   |                 |    |
| pT1                      | 12 (24)           | 18 (36)         | 0.2|
| pT2                      | 32 (64)           | 30 (60)         |    |
| pT3                      | 6 (12)            | 2 (4)           |    |
| Nodal status (n, %)      |                   |                 |    |
| pN0                      | 19 (38)           | 15 (30)         | 0.2|
| pN1                      | 17 (34)           | 24 (48)         |    |
| pN2                      | 6 (12)            | 8 (16)          |    |
| pN3                      | 8 (16)            | 3 (6)           |    |
| Mastectomy (n, %)        |                   |                 |    |
| Yes                      | 28 (56)           | 34 (68)         | 0.2|
| No                       | 22 (44)           | 16 (32)         |    |
| Histology (n, %)         |                   |                 |    |
| Ductal                   | 44 (88)           | 45 (90)         | 0.2|
| Lobular                  | 5 (10)            | 1 (2)           |    |
| Mixed                    | 0 (–)             | 2 (4)           |    |
| Other                    | 1 (2)             | 2 (4)           |    |
| Molecular subtype by IHC (n, %) |           |                 |    |
| Luminal A                | 13 (26)           | 9 (18)          | 0.3|
| Luminal B                | 25 (50)           | 30 (60)         |    |
| HER2+                    | 8 (16)            | 6 (12)          |    |
| Triple negative          | 4 (8)             | 5 (10)          |    |
| Grade (n, %)             |                   |                 |    |
| 1                        | 4 (8)             | 3 (6)           | 0.8|
| 2                        | 23 (46)           | 26 (52)         |    |
| 3                        | 23 (46)           | 21 (42)         |    |
| Peritumoral vascular invasion (n, %) |        |                 |    |
| 0                        | 31 (62)           | 23 (46)         | 0.3|
| 1                        | 9 (18)            | 9 (18)          |    |
| 2                        | 9 (18)            | 16 (32)         |    |
| 3                        | 1 (2)             | 2 (4)           |    |
| HER2 overexpression/amplification (n, %) |        |                 |    |
| Yes                      | 8 (16)            | 6 (12)          | 0.6|
| No                       | 42 (84)           | 44 (88)         |    |

Abbreviations: IHC = immunohistochemistry; IQR = interquartile range; LI = labelling index.

*Wilcoxon rank-sum or Pearson’s χ²-test.

Figure 1. Boxplots of TUNEL levels by allocated arm at baseline and surgery. No difference between arms was noted (P = 0.2, adjusted for age, BMI, baseline TUNEL and Ki67 LI). Median TUNEL levels were significantly higher at surgery compared with baseline biopsy in both arms (P < 0.0001).
The highly statistically significant direct correlation between Ki67 LI levels and TUNEL confirms the observation in several tumour types that cellular proliferation is accompanied by an increase of programmed cell death as a mechanism limiting a dimensional and faster abnormal growth of the neoplastic burden (Tan et al, 2005). Although metformin has been shown to promote cell death with an independent mechanism involving a direct activation of the apoptotic pathway in some studies (Zhuang and Miskimins, 2011), our findings suggest that an increased apoptosis is associated with an increased proliferation also in BC.

A close positive relationship between Ki67 LI and TUNEL has also been noted by the borderline significant interaction between metformin and HOMAi on TUNEL, resulting in a dual modulation according to insulin resistance status, similar to that which was noted in Ki67. We found a trend to a lower increase of TUNEL in insulin-resistant women under metformin relative to placebo and an opposite effect in non-insulin-resistant patients where TUNEL increased more under metformin compared with placebo. The decreasing trend in BC proliferation and apoptosis in women with high HOMAI under metformin suggests that indirect, insulin- and glucose-mediated effects are an important mechanism of the anticancer effect of metformin in human BC. Our results are consistent with the diabetes prevention trial (Knowler et al, 2002), where metformin had a significantly heterogeneous effect on diabetes onset according to baseline BMI and glucose levels, with a greater effect in obese and severely glucose-intolerant women.

Our findings strengthen the importance of a control arm in biomarker trials in order to adjust for the biological and technical variability of biomarkers. In the placebo arm of our trial, both Ki67 and TUNEL were significantly higher in the surgical sample compared with baseline. The increase in Ki67 LI within the placebo groups a few weeks apart has been associated with the most highly proliferating molecular subtypes (triple-negative and HER2-positive BC; Tagliabue et al, 2003; Gandini et al, 2013), suggesting a true biological increase in proliferation rather than a technical artifact due to different tissue sampling.

Our results differ from those obtained by Niraula et al (2012) who showed an increase in TUNEL along with a decrease in Ki67 LI after metformin treatment. Although we do not have a ready explanation for these differences, their study had a more limited sample (39 patients) and no control group. In addition, most patients were overweight or obese, in contrast to our study where only one quarter had those characteristics. Perhaps most importantly, different tumour characteristics and assay methods are likely, as our median Ki67 LI was nearly 50% lower and median TUNEL levels were ~10 times higher compared with those of Niraula et al (2012). Our laboratory was among those that

Figure 2. Boxplots of TUNEL levels by allocated arm and HOMAi according to a cutoff level of 2.8. The interaction between treatment and HOMAi was borderline significant ($P = 0.1$).

Figure 3. Correlation between Ki67 and TUNEL values at baseline in all study patients regardless of treatment arm (Spearman’s $r = 0.5$, $P < 0.0001$).

Figure 4. Correlation between Ki67 and TUNEL values at surgery in all study patients regardless of treatment arm (Spearman’s $r = 0.5$, $P < 0.0001$).
contributed to the recently published guidelines for the Ki67 measurement (Dowsett et al, 2011), which is known to be subject to a high variability. A potential limitation of our study is the drug cessation 24 h or longer before surgery, which was dictated by safety reasons (Drugs.com, 2011 http://www.drugs.com/pro/metformin.html). However, the finding of a selective effect of metformin only in insulin-resistant women weakens the criticism. Moreover, metformin can reach higher tissue/blood concentrations (Nestler, 2008), which should not decrease its biological effects up to several days from drug cessation. Finally, we had previously shown no significant association between any circulating biomarker changes and the interval from treatment cessation (Bonanni et al, 2012). If anything, the wash-out diluted our findings towards the null hypothesis without affecting overall conclusions.

CONCLUSIONS

These findings are hypothesis-generating and cannot have immediate clinical implications, but may have important public health implications in the near future. Indeed, the effects of metformin in insulin-resistant and/or obese women could be substantial and supportive of cancer therapeutic and preventive studies in women with these characteristics. This is especially important because the prevalence of obesity is rapidly increasing globally and has reached epidemic proportions in developed countries (Low et al, 2009). A phase III adjuvant trial is currently underway to determine the overall therapeutic effect of metformin and whether it differs according to obesity and insulin resistance (Goodwin et al, 2011). The results of this trial will shed light upon the cancer therapeutic effect of this fascinating drug.

ACKNOWLEDGEMENTS

The study was supported by grants from the Italian Association for Cancer Research AIRC (IG 12072), the Italian Ministry of Health (RF-2009-1532226) and the Italian League Against Cancer (14/08).

CONFLICT OF INTEREST

The authors declare no conflict of interest.

REFERENCES

Bonanni B, Puntoni M, Cazzaniga M, Pruneri G, Serrano D, Guerrieri-Gonzaga A, Gennari A, Trabacca MS, Galimberti V, Veronesi P, Johansson H, Arisztaro V, Bassi F, Luini A, Lazzeroni M, Varricchio C, Viale G, Bruzzi P, Decensi A (2012) Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol 30: 2593–2600.

Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Targher G, Alberiche M, Bosco JL, Antonsen S, Sorensen HT, Pedersen L, Lash TL (2011) Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res 3: 1451–1461.

Dowsett M, Nielsen TO, A’Hern R, Bartlett J, Coombes RC, Cuzick J, Ellis M, Henry NL,Hugh JC, Lively T, McShane L, Paik S, Pentaur-Lorca F, Prudkin L, Regan M, Saltjer J, Sotiriou C, Smith IE, Viale G, Zuwajew JA, Hayes DF, International Ki67 in Breast Cancer Working Group (2011) Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast cancer working group. J Natl Cancer Inst 103: 1656–1664.

Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330: 1304–1305.

Gandini S, Guerrieri-Gonzaga A, Pruneri G, Serrano D, Cazzaniga M, Lazzeroni M, Veronesi P, Johansson H, Bonanni B, Viale G, Decensi A (2013) Association of molecular subtypes with Ki-67 changes in untreated breast cancer patients undergoing pre-surgical trial. Ann Oncol (in press).

Gonzalez-Angulo AM, Meric-Bernstam F (2011) Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res 16: 1695–1700.

Goodwin PJ, Liliget JA, Stambolic V (2009) Metformin in breast cancer: time for action. J Clin Oncol 27: 3271–3273.

Goodwin PJ, Pritchard KI, Ennis M, Clemons M, Graham M, Fantus IG (2008) Insulin-lowering effects of Metformin in women with early breast cancer. Clin Cancer Res 8: 501–505.

Goodwin PJ, Stambolic V, Lemieux J, Chen BE, Parulekar WR, Gelman KA, Hershman DL, Hobday TJ, Liliget JA, Mayer IA, Pritchard KI, Whelan TJ, Rastogi P, Shepherd LE (2011) Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents. Breast Cancer Res Treat 126: 215–220.

Gunter MJ, Hoover DR, Yu H, Wartell-Smoller S, Rohan TE, Manson JE, Li J, Ho GY, Xue X, Anderson GL, Kaplan RC, Harris TG, Howard BV, Wylie-Rosett J, Burk RD, Strickler HD (2009) Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women. J Natl Cancer Inst 101: 48–60.

Guppy A, Jamal-Hanjani M, Pickering L (2011) Anticancer effect of metformin and its potential use as a therapeutic agent for breast cancer. Future Oncol 7: 727–736.

Jiralespons P, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi GN, Gonzalez-Angulo AM (2009) Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27: 3297–3302.

Johnson JA, Gale EA (2010) Diabetes, insulin use, and cancer risk: are observational studies the solution or part of the problem? Diabetes 59: 1129–1131.

Knolwer WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM. Diabetes Prevention Program Research Group (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention of metformin. New Engl J Med 346: 393–403.

Low S, Chin MC, Deurenberg-Yap M (2009) Review on epidemic of obesity. Ann Acad Med Singapore 38: 57–65.

Mulligan AM, O’Malley FP, Ennis M, Fantus IG, Goodwin PJ (2007) Insulin receptor is an independent predictor of a favorable outcome in early stage breast cancer. Breast Cancer Res Treat 106: 39–47.

Nestler JE (2008) Metformin for the treatment of the polycystic ovary syndrome. New Engl J Med 358: 47–54.

Niraula S, Dowling RJ, Ennis M, Chang MC, Done SJ, Hood N, Escallon J, Leong WL, McCready DR, Reedijk M, Stambolic V, Goodwin PJ (2012) Metformin in early breast cancer: a prospective window of opportunity neoadjuvant study. Breast Cancer Res Treat 135: 821–830.

Pollak MN, Schernhammer ES, Hankinson SE (2004) Insulin-like growth factors and neoplasia. Nat Rev Cancer 4: 505–518.

Renehan AG, Frystyk J, Flyvbjerg A (2006) Obesity and cancer risk: the role of the insulin-IGF axis. Trends Endocrinol Metab 17: 328–336.

Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M (2008) Body mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 371: 569–578.

Sahra IB, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auribeau P, Tanti JF, Le Marchand-Brustel Y, Bost F (2008) The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene 27: 3576–3586.
Soranna D, Scotti L, Zambon A, Bosetti C, Grassi G, Catapano A, La Vecchia C, Mancia G, Corrao G (2012) Cancer risk associated with use of metformin and sulfonylurea in type 2 diabetes: a meta-analysis. Oncologist 17: 813–822.

Tagliabue E, Agresti R, Carcangiu ML, Ghirelli C, Morelli D, Campiglio M, Martel M, Giovanazzi R, Greco M, Balsari A, Ménard S (2003) Role of HER2 in wound-induced breast carcinoma proliferation. Lancet 362: 527–533.

Tan PH, Bay BH, Yip G, Selvarajan S, Tan P, Wu J, Lee CH, Li KB (2005) Immunohistochemical detection of Ki67 in breast cancer correlates with transcriptional regulation of genes related to apoptosis and cell death. Mod Pathol 18: 374–381.

Vander Heiden MG, Cantley LC, Thompson CB (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324: 1029–1033.

Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M (2006) Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66: 10269–10273.

Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Meally J, Wu M, Ventsre J, Doebber T, Fuji N, Musi N, Hirshman MF, Goodyer LJ, Moller DE (2001) Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108: 1167–1174.

Zhuang Y, Miskimins WK (2011) Metformin induce both caspase-dependent and poly(ADP-ribose)polymerase-dependent cell death in breast cancer cells. Mol Cancer Res 9: 603–615.

Yee D (2006) Targeting insulin-like growth factor pathways. Br J Cancer 94: 465–468.

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.

Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)